Key points
- Revenue from ordinary activities increased by 68% to $8,004,000
- Loss from ordinary activities after tax rose by 67% to $107,242,000
- No dividends declared during the financial year
- Net tangible assets per ordinary security increased to 49.9 cents
- Loss of control over Clarity Pharmaceuticals Europe SA on 31 December 2025
Full summary
Clarity Pharmaceuticals Ltd, a clinical-stage radiopharmaceutical company, announced its preliminary final report for the year ending 30 June 2026. The company reported a 68% increase in revenue from ordinary activities to $8,004,000, while the loss from ordinary activities after tax rose by 67% to $107,242,000. Clarity Pharmaceuticals did not declare any dividends during the financial year. The company's net tangible assets per ordinary security increased to 49.9 cents. Clarity Pharmaceuticals also reported the loss of control over Clarity Pharmaceuticals Europe SA on 31 December 2025.
Guidance
Loss from ordinary activities after tax up 67% to $107,242,000 for FY2026
Outlook
Clarity Pharmaceuticals remains focused on advancing its clinical trials and commercialization efforts, with a strong financial position to support its programs throughout FY2027. The company is progressing through late-stage clinical trials, expanding its manufacturing and supply capability, and growing its team to ensure a seamless transition into the market. Clarity Pharmaceuticals is well funded with a cash balance of $156 million as at the date of this report.